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Hair loss (alopecia) is a much-feared side-e¡ect of
many chemotherapy protocols and is one of the most
psychological devastating aspects of cancer therapy. So
far, no satisfactory strategy for suppressing chemother-
apy-induced alopecia is at hand. During the last decade,
some progress in understanding molecular mechanisms
of chemotherapy-induced hair loss has been achieved
using rodent models. However, the pathobiology of the
response of human hair follicle to chemotherapy re-
mains largely unknown. Here, we review molecular
mechanisms that control apoptosis in the hair follicle
induced by chemotherapy and delineate the basic strategy
for pharmacological inhibition of this devastating side-
e¡ect of cancer treatment.We focus on the roles of p53
and its target genes that are essential in mediating
responses of hair follicle cells. We assume that local
pharmacological inhibition of p53 activity may serve
as an e¡ective treatment to prevent chemotherapy-in-
duced hair loss. Su⁄cient pharmacological inhibi-
tion of chemotherapy-induced hair loss may require
a combination of inhibitors to block complementary
or redundant pathways of apoptosis in hair folli-
cles. Keywords: hair follicle/apoptosis/cataben/cyclophospha-
mide. JID Symposium Proceedings 8:72 ^75, 2003
I
nduction of massive hair loss (alopecia) by many che-
motherapeutic drugs ranks among the most psychologically
devastating side-e¡ects of cancer treatment (Kiebert et al,
1990; Macquart-Moulin et al, 1997). More than 80% of
patients who receive chemotherapy consider hair loss the
most distressing aspect of their treatment (Kiebert et al, 1990;
Macquart-Moulin et al, 1997). So far, no satisfactory startegy for
suppressing chemotherapy-induced alopecia in man is at hand.
Although scalp hypothermia and pharmacological treatment with
minoxidil or calcitriol have been proposed, several studies have
shown their ine¡ectiveness in clinical practice (Hubbard, 1985;
Hidalgo et al, 1999). During last decade, progress in understanding
molecular mechanisms of chemotherapy-induced hair loss has
been achieved, using rodent models (Paus et al, 1994; Botchkarev
et al, 2000b; Davis et al, 2001). However, the pathobiology of the
response of human hair follicle (HF) to chemotherapy remains
largely unknown. In this review, we focus on molecular mechan-
isms that control apoptosis in the HF following chemotherapy
and delineate a strategy for pharmacological inhibition of this
devastating side-e¡ect.
PATHOBIOLOGYOF CHEMOTHERAPY-INDUCED
HAIR LOSS
In human skin, hair loss (alopecia) starts approximately 2^4
weeks after the initial course of chemotherapy, and hair usually
begin to regrow 3^6 months after the end of treatment (Hub-
bard, 1985; Hussein, 1993). The degree of hair loss depends on
the drug used, doses, and schedules of administration. Drugs
with high potential for inducing alopecia include cyclophospha-
mide, doxorubicin, cisplatin, cytosine arabinoside, and etoposide
(Hubbard, 1985; Hussein, 1993). This is most often seen with sys-
temic chemotherapy, but can occur even after topical application
of chemotherapeutic agents.
Due to ethical problems in obtaining scalp biopsies from pa-
tients treated with chemotherapy, little is known about mechan-
isms of apoptosis induced by chemotherapeutic agents in human
HF. Usually, 2^4 weeks after beginning chemotherapy, hair shafts
break o¡ almost as soon as they issue from anagen follicles (ana-
gen e¥uvium). Obviously, anticancer drugs impair mitotic and
metabolic processes in actively growing hair follicles leading to
the thinning of hair shaft, which becomes fragile and susceptible
to fracture with minimal trauma. Later, HF in chemotherapy-
a¡ected skin undergo apoptosis-driven regression (catagen)
followed by the resting period (telogen) (Hubbard, 1985; Hussein,
1993). Much of this important information comes from animal
models for chemotherapy-induced hair loss established during
last decade. Below, we review data obtained from these models.
Chemotherapy-induced hair loss in newborn rat model
The ¢rst model for chemotherapy-induced hair loss was
established in newborn rats (Hussein et al, 1990; Hussein, 1995).
In this model, administration of di¡erent chemotherapeutic
agents (cytosine arabinoside, doxorubicin, cyclophosphamide,
etoposide) induced hair loss one week after beginning treatment
(Hussein et al, 1990; Hussein, 1991; Jimenez and Yunis, 1992b). It
was also shown that doxorubicin a¡ects proliferation in the HF
matrix cells and induces apoptosis followed by hair loss (Cece
et al, 1996). Partial protection against cytosine arabinoside-
induced hair loss was achieved by local administration of a
variety of chemicals (N-acetylcysteine, minoxidil) and growth
factors (interleukin-1b, EGF, FGF1) (Hussein et al, 1990; Jimenez
and Yunis, 1992a; Jimenez and Yunis, 1992b; JimeŁ nez et al, 1992;
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Hussein, 1995). It was recently shown that cyclin-dependent
kinase inhibitors can induce partial protection against etoposide-
induced hair loss in newborn rats (Davis et al, 2001).
However, many exciting observations obtained using the
newborn rat model for chemotherapy-induced hair loss appear
irrelevant or less relevant for mice and humans. For instance,
topical application of 1,25-dihydroxyvitamin D3 shown to be
e¡ective in preventing cyclophosphamide-induced hair loss in
newborn rats (Jimenez and Yunis, 1992b; Jimenez et al, 1995),
failed to prevent or retard hair loss in C57BL/6 mice or in
human scalp after cyclophosphamide administration (Paus et al,
1996; Hidalgo et al, 1999). In addition, a serious limitation of this
model is the unavailability of rat mutants with constitutive
deletion of genes suspected to mediate chemotherapy-induced
apoptosis in the HF.
C57BL/6 mouse model for chemotherapy-induced hair loss
The greatest amount of progress in understanding the
pathobiology of chemotherapy-induced hair loss has been
achieved using the C57BL/6 mouse model developed in Ralf
Paus’s laboratory (Paus et al, 1994; Paus et al, 1996; Schilli et al,
1998). In this model, a single intraperitoneal injection of 150 mg/kg
cyclophosphamide induces severe alopecia in postnatal mice with
HF previously synchronized in anagen phase by depilation (Paus
et al, 1994). In a dose-dependent manner, cyclophosphamide
induces dystrophic changes in growing HF, or in more severely
damaged follicles premature regression leads to hair loss. After
cyclophosphamide administration, keratinocytes of the hair
matrix, outer and inner root sheaths and follicular melanocytes
show aberrant expression of ‘‘death’’ receptors and massive un-
coordinated apoptosis (Slominski et al, 1996; Lindner et al, 1997;
Tobin et al, 1998).
In C57BL/6 mice, distinct HF cell populations display di¡erent
sensitivities to cyclophosphamide.While keratinocytes of the hair
matrix, outer and inner root sheath show massive apoptosis after
cyclophosphamide administration, dermal papilla ¢broblasts
appear to be resistant to apoptosis (Slominski et al, 1996; Lindner
et al, 1997; Tobin et al, 1998). Cyclophosphamide also induces up-
regulation of ‘‘death’’ receptors (Fas/Apo-1, p55TNFR) and the
mitochondrial protein Bax in HF (Lindner et al, 1997). Fas/Apo-1
is increased in the HF outer root sheath of cyclophosphamide-
treated hair follicles, while pro-apoptotic Bax is up-regulated
and Bcl-2 is down-regulated in the outer and inner root sheath,
hair matrix and dermal papilla (Lindner et al, 1997). However, the
presumptive roles for apoptotic receptors and intracellular
signaling molecules in chemotherapy-induced hair loss remain
largely unknown.
p53 IS ESSENTIAL FORCHEMOTHERAPY-INDUCED
HAIR LOSS IN MICE
p53 is a transcription factor and tumor suppressor protein that
plays a critical role in mediating apoptotic cell death induced by
chemotherapeutic agents (Lakin and Jackson, 1999). Levels of p53
rise dramatically within one hour after a cell sustains DNA da-
mage, mostly due to post-translational regulation (Kastan et al,
1991). Activation of p53 in response to DNA damage is associated
with degradation of the Mdm2/p53 complex, followed by an in-
creased ability of p53 to bind DNA and consequently increased
transcription of p53 target genes involved in apoptotic cell
death.
By inducing proteins acting at the receptor signaling level, p53
may sensitize cells to apoptosis. p53 up-regulates transcription of
the important ‘‘death-domain’’ receptor Fas/Apo-1/CD95, and p53
responsive elements have been identi¢ed in the Fas gene (Friesen
et al, 1996; Burns and El-Deiry, 1999). Chemotherapy-induced
DNA damage is also accompanied by up-regulation of the Fas-
ligand (Muller et al, 1997;Waring and Mullbacher, 1999). Further-
more, during DNA damage induced by chemotherapeutic agents,
p53 up-regulates expression of IGF-BP3, suppresses activity of
the IGF-RI promoter, and thus decreases the pro-survival activity
of IGF-1 protein (Buckbinder et al, 1995;Werner et al, 1998; Brown
andWouters, 1999; Sionov and Haupt, 1999).
p53 is also involved in the transcriptional control of genes
mediating mitochondrial changes during apoptotic cell death in-
duced by chemotherapeutic agents (Asker et al, 1999; Brown and
Wouters, 1999; Burns and El-Deiry, 1999; Sionov and Haupt,
1999). p53 up-regulates transcription of Bax and down-regulates
transcription of Bcl-2, thus decreasing the Bcl-2/Bax ratio and
predisposing cells to apoptosis (Miyashita et al, 1994; Miyashita
and Reed, 1995). Interestingly, many proteins encoded by p53
target genes (Fas, Bax, insulin growth factor receptor type I
(IGF-RI), insulin-like growth factor binding protein 3 (IGF-
BP3)) are expressed in the hair follicle and are up-regulated after
cyclophosphamide administration (Lindner et al, 1997). p53 is in-
volved in the control of spontaneous hair regression. (Botchkarev,
2001). Therefore, it was logical to suppose that p53 is involved in
mediating DNA damage responses in the HF induced by che-
motherapeutic agents.
p53 is essential for cyclophosphamide-induced apoptosis
in the HF Using a mouse model for chemotherapy-induced
hair loss, we demonstrate that p53 plays a key role in mediating
cyclophosphamide-induced apoptosis in the HF (Botchkarev
et al, 2000). In contrast to untreated late anagen HF, cyclo-
phosphamide-treated HF display strong up-regulation of p53 in
the proximal outer and inner root sheaths and hair matrix,
including many TUNEL-positive apoptotic cells (Botchkarev
et al, 2000). Furthermore, in contrast to wild type mice, p53-
de¢cient mice show neither hair loss nor apoptosis in hair
matrix keratinocytes, which maintain active proliferation after
cyclophosphamide treatment.
p53 target genes are involved in chemotherapy-induced
apoptosis in HF As is true for other sensitive tissues, the exact
mechanism of p53-dependent apoptosis in the HF remains
unclear. It may involve several p53 responsive genes acting
through di¡erent mechanisms. Comparative analyses of proteins
encoded by p53 target genes followed by cyclophosphamide
treatment suggest that p53 null HF are characterized by a down-
regulation of Fas and IGF-BP3 and an increased expression of
Bcl-2, compared to wild-type controls (Botchkarev et al, 2000).
More recent data suggest an important role for Fas, particularly
in chemotherapy-induced apoptosis.1 A signi¢cant retardation of
cyclophosphamide-induced HF regression was observed in Fas
knockout mice, compared to wild-type mice. Also, cyclophos-
phamide-induced apoptosis in hair matrix keratino-cytes of
C57BL/6 mice is signi¢cantly reduced after administration
of Fas-ligand neutralizing antibody. In addition Fas mediates
cyclophosphamide induced apoptosis in hair follicle melano-
cytes. (Sharov et al, 2003).
p21CIP1/WAF1, another p53 target gene that is up-regulated
during cellular responses to DNA damage, mediates p53-
dependent G1 arrest (El-Deiry et al, 1993; Lakin and Jackson,
1999). Accumulation of p21 in cells after DNA damage results in
binding and inactivation of the cyclin-dependent kinase 2
(CDK2)/cyclin E complex, which, in turn, leads to inhibition of
G1/S progression (reviewed in Ekholm and Reed, 2000).
Although p21 protein was not found in replicating hair matrix
keratinocytes, a major target for chemotherapeutic agents (Song
and Lambert, 1999), chemical CDK2 inhibitors signi¢cantly
reduced hair loss induced by etoposide in the newborn rat
model (Davis et al, 2001). This suggests that G1 arrest in hair
matrix keratinocytes induced by chemotherapeutic agents is
likely mediated by other endogenous CDK2/cyclin E inhibitors
1 Botchkarev VA, Siebenhaar F, Sharov AA, Komarova Ea, Maurer M,
Gudkov AV, Gilchrest BA: Molecular mechanisms of chemotherapy-in-
duced hair loss: Essential roles for p53 and its target genes. J Invest Dermatol
117: 428 [abstract] 2001
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(p27, p57, or Cdc25A phosphatase; reviewed in Bartek and Lukas,
2001).
PHARMACOLOGICAL MODULATION OF
CHEMOTHERAPY-INDUCED HAIR LOSS
Numerous attempts to inhibit HF responses to chemotherapeutic
agents using local or systemic administration of chemicals
(N-acetylcysteine, minoxidil), growth factors (interleukin-1b,
EGF, FGF1) or 1,25-dihydroxyvitamin D3 have shown only
relative protective e¡ects in rodent models (Hussein et al, 1990;
Jimenez and Yunis, 1992a; Jimenez and Yunis, 1992b; Hussein,
1995; Jimenez et al, 1995; Paus et al, 1996). This suggests that major
apoptotic pathways induced in the HF by chemotherapy are not
targeted by these substances.
Because p53 is essential for chemotherapy-induced hair
loss in mice (Botchkarev et al, 2000), pharmacological inhibition
of p53 functions in the HF may be an alternative and promising
strategy to prevent chemotherapy-induced hair loss. It was
recently shown that application of a chemical inhibitor reduces
the toxicity of cancer treatment in experimental animals by tem-
porary reversible suppression of p53 (Komarov et al, 1999). These
observations suggest that local inhibition of p53 by p53 antago-
nist molecules may be useful in preventing chemotherapy-in-
duced hair loss.
As shown in many models, chemotherapeutic drugs induce
growth arrest in target cells (Mesner et al, 1997). Chemotherapeu-
tic agents may induce G1 growth arrest in HF cells, and pharma-
cological inhibition of CDK2 activity by chemical CDK2
inhibitors was shown to signi¢cantly retard hair loss induced by
etoposide in newborn rat model (Davis et al, 2001). In this con-
text, it will be very interesting to combine p53 antagonists with
CDK inhibitors (Komarov et al, 1999; Davis et al, 2001) to prevent
both apoptosis and growth arrest in HF exposed to chemothera-
peutic agents.
In designing strategies for pharmacological inhibition of
chemotherapy-induced hair loss, one should take into considera-
tion that p53-independent mechanisms may also be involved
in mediating HF responses. For example, it was shown that cis-
platin up-regulates expression of other members of the p53
family, namely p73 and tyrosine kinase c-Abl, which mediate
p53-independent apoptosis in tumor cells (Gong et al, 1999).
Furthermore, accumulating data suggest that p53-independent
pathways play important roles in mediating apoptosis induced
in tumor cells by doxorubicin (reviewed in Perego et al,
2001). This suggests that the problem of pharmacological inhibi-
tion of chemotherapy-induced hair loss is much more complex
than previously appreciated and may require a distinct combina-
tion of apoptotic inhibitors for every chemotherapeutic agent
used.
It appears that inhibiting chemotherapy-induced hair loss will
require further progress in several areas. First, development of a
human model for chemotherapy-induced hair loss assures the re-
levance that is essential in studying molecular mechanisms of
apoptosis induced by chemotherapeutic agents. Second, a variety
of apoptotic inhibitors need to be tested singly and in combina-
tion after exposure of human HF to di¡erent chemotherapeutic
drugs used in clinical practice. Third, it must be determined
whether local administration of apoptosis inhibitors to prevent
or retard chemotherapy-induced hair loss a¡ects the antitumor
activity of chemotherapeutic agents. Motivation for such a com-
prehensive program of research has the potential of improving
psychological status of patients by sparing them the side-e¡ect
of hair loss during their cancer therapy.
REFERENCES
Asker C, Wiman KG, Selivanova G: p53-induced apoptosis as a safeguard against
cancer. Biochem Biophys Res Commun 265:1^6, 1999
Bartek J, Lukas J: Pathways governing G1/S transition and their response to DNA
damage. FEBS Lett 490:117^122, 2001
BotchkarevVA, Komarova EV, Siebenhaar F, et al: p53 is essential for chemotherapy-
induced hair loss. Cancer Res 60:5002^5006, 2000
BotchkarevVA, Komarova EV, Siebenhaar F, et al: p53 involvement in the control of
murine hair follicle regression. AmJ Pathol 158:1913^1919, 2001
Brown JM, Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer
agents. Cancer Res 59:1391^1399, 1999
Buckbinder L,Talbot R,Velascomiguel S,Takenaka I, Faha B, Seizinger BR, Kley N:
Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature
391:646^649, 1995
Burns TF, El-Deiry WS: The p53 pathway and apoptosis. J Cell Physiol 181:231^239,
1999
Cece R, Cazzaniga S, Morelli D, et al: Apoptosis of hair follicle cells during doxor-
ubicin-induced alopecia in rats. Lab Invest 75:601^609, 1996
Davis ST, Benson BG, Bramson HN, et al: Prevention of chemotherapy-induced alo-
pecia in rats by CDK inhibitors. Science 291:134^137, 2001
Ekholm SV, Reed SI: Regulation of G1 cyclin-dependent kinases in the mammalian
cell cycle. Curr Opin Cell Biol 12:676^684, 2000
El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of of p53
tumor suppression. Cell 75:817^825, 1993
Friesen C, Herr I, Krammer PH, Debatin KM: Involvement of the CD95 (APO-1/
FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.
Nature Med 2:574^577, 1996
Gong JG, Costanzo A,Yang H-Q, Melino G, KaelinWJ, Levrero M,Wang JYI: The
tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced
DNA damage. Nature 399:806^809, 1999
Hidalgo M, Rinaldi D, Medina G, Gri⁄n T,Turner J,Von Ho¡ DD: A phase I trial
of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent che-
motherapy-induced alopecia. Anticancer Drugs 10:393^395, 1999
Hubbard SM: Chemotherapy-induced alopecia. Clin Oncol 4:387^457, 1985
Hussein AM: Chemotherapy-induced alopecia: New developments. Southern Med J
86:489^496, 1993
Hussein AM: Interleukin-1 protects against 1-beta-D-Arabinofuranosylcytosine-
induced alopecia in the newborn rat animal model. Cancer Res 51:3329^3330,
1991
Hussein AM: Protection against cytosine arabinoside-induced alopecia by minoxidil
in a rat animal model. Int J Dermatol 34:470^473, 1995
Hussein AM, Jimenez JJ, McCall CA,Yunis AA: Protection from chemotherapy-in-
duced alopecia in a rat model. Science 249:1564^1566, 1990
Jimenez JJ, Alvarez E, Bustamante CD,Yunis AA: Pretreatment with 1,25 (OH) 2D3
protects from cytoxan-induced alopecia without protecting the leukemic cells
from cytoxan. AmJ Med Sci 310:43^47, 1995
JimeŁ nez JJ, Huang HS,Yunis AA:Treatment with ImuVert/N-acetylcysteine protects
rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest 10:
271^276, 1992
Jimenez JJ, Yunis AA: Protection from 1-beta-d-Arabinofuranosylcytosine-induced
alopecia by epidermal growth factor and ¢broblast growth factor in the rat
model. Cancer Res 52:413^415, 1992a
Jimenez JJ,Yunis AA: Protection from chemotherapy-induced alopecia by 1,25-dihy-
droxyvitamin D3. Cancer Res 52:5123^5125, 1992b
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of
p53 protein in the cellular response to DNA damage. Cancer Res 51:6304^6311,
1991
Kiebert GM, Hanneke J, de Haes CJ, Kievit J, van deVelde CJ: E¡ect of perioperative
chemotherapy on the quality of life of patients with early breast cancer. Eur J
Cancer 26:1038^1042, 1990
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov
MV, GudkovAV: A chemical inhibitor of p53 that protects mice from the side
e¡ects of cancer therapy. Science 285:1733^1737, 1999
Lakin ND, Jackson SP: Regulation of p53 response to DNA damage. Oncogene
18:7644^7655, 1999
Lindner G, BotchkarevVA, Botchkareva NV, Ling G, van der Veen C, Paus R: Ana-
lysis of apoptosis during hair follicle regression (catagen). AmJ Pathol 151:1601^
1617, 1997
Macquart-Moulin G,Viens P, Bouscary M-L, et al: Discordance between physicians’
estimations and breast cancer patients’ self-assessment of side-e¡ects of che-
motherapy: an issue for quality of care. Br J Cancer 76:1640^1645, 1997
Mesner PWJ, Budihardjo II, Kaufmann SH: Chemotherapy-induced apoptosis. Adv
Pharmacol 41:461^469, 1997
Miyashita T, Harigai M, Hanada M, Reed JC: Identi¢cation of a p53-dependent ne-
gative response element in the Bcl-2 gene. Cancer Res 54:3131^3135, 1994
MiyashitaT, Reed JC:Tumor suppresor protein is a direct transcriptional activator of
human bax gene. Cell 80:293^299, 1995
Muller M, Strand S, Hug H: Drug-induced apoptosis in hepatoma cells is mediated
by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of
wild-type p53. J Clin Invest 99:403^413, 1997
Paus R, Handjiski B, Eichmuller S, Czarnetzki BM: Chemotherapy-induced alope-
cia in mice Induction by cyclophosphamide, inhibition by cyclosporine A, and
modulation by dexamethasone. AmJ Pathol 144:719^734, 1994
Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P: Topical calcitriol
enhances normal hair regrowth but does not prevent chemotherapy-induced
alopecia in mice. Cancer Res 56:4438^4443, 1996
74 BOTCHKAREV JID SYMPOSIUM PROCEEDINGS
Perego P, Corna E, Decesare M, et al: Role of apoptosis and apoptosis-related genes
in cellular response and antitumour e⁄cacy of anthracyclines. Curr Med Chem
8:31^37, 2001
Schilli MB, Paus R, Menrad A: Reduction of intrafollicular apoptosis in chemother-
apy-induced alopecia by topical calcitriol-analogs. J Invest Dermatol 111:598^604,
1998
Sharov A, Li GZ, Palkina TN, Sharova TY, Gilchrest BA, Botchkarev VA: Fas and
C-kit are involved in the control of hair follicle melanocyte apaptosis and mi-
gration in chemotherapy-induced hair loss. J Invest Dermatol 120:27^35, 2003
Sionov RV, Haupt Y: The cellular response to p53. The decision between life and
death. Omcogene 18:6145^6157, 1999
Slominski A, Paus R, Plonka P, Handjiski B, Maurer M, Chakraborty A, Mihm
MCJ: Pharmacological disruption of hair follicle pigmentation by cyclopho-
sphamide as a model for studying the melanocyte response to and
recovery from cytotoxic drug damage in situ. J Invest Dermatol 106:1203^1211,
1996
Song S, Lambert PF: Di¡erent responses of epidermal and hair follicle cells to radia-
tion correlate with distinct patterns of p53 and p21 induction. Am J Pathol
155:1121^1127, 1999
Tobin DJ, Hagen E, Botchkarev VA, Paus R: Do hair bulb melanocytes undergo
apoptosis during hair follicle regression (catagen)? J Invest Dermatol 111:
941^947, 1998
Waring P, Mullbacher A: Cell death induced by the Fas/Fas ligand pathway and its
role in pathology. Immunol Cell Biol 77:312^317, 1999
Werner H, Karnieli E, Rauscher FJ, LeRoith D:Wild-type and mutant p53 diferen-
tially regulate transcription of the insulin-like growth factor I receptor gene.
Proc Natl Acad Sci USA 93:8318^8323, 1998
MOLECULAR MECHANISMS OF CHEMOTHERAPY-INDUCED HAIR LOSS 75VOL. 8, NO. 1 JUNE 2003
